Bellmunt J, González-Larriba J L, Climent M A, López-Vivanco G, Urruticoechea L, Albanell J
Servicio de Oncología. Hospital General Universitari Vall d'Hebrón. Barcelona, Spain.
Clin Transl Oncol. 2007 Oct;9(10):671-3. doi: 10.1007/s12094-007-0120-6.
Sorafenib improves progression-free survival in advanced clear-cell renal-cell carcinoma patients progressing to first-line therapy, as has been shown in the placebo-controlled international TARGET trial. The aim of this study is to report the results of the patients included in the Spanish centres in this trial.
The records of the patients in the database of the TARGET trial have been reviewed. Data about progression-free survival, overall survival and toxicity have been collected in order to do this subpopulation analysis.
A total of 15 patients have been included (sorafenib arm 7, placebo arm 8). A trend to an improved progression-free survival in the sorafenib arm has been observed period Toxicity in the sorafenib arm has been manageable.
The analysis of these 15 patients has shown efficacy and toxicity results that follow the trend observed for the overall international population.
在安慰剂对照的国际 TARGET 试验中已表明，索拉非尼可改善一线治疗进展后的晚期透明细胞肾细胞癌患者的无进展生存期。本研究的目的是报告该试验中西班牙中心纳入患者的结果。
回顾了 TARGET 试验数据库中患者的记录。为进行该亚组分析，收集了有关无进展生存期、总生存期和毒性的数据。
共纳入 15 例患者（索拉非尼组 7 例，安慰剂组 8 例）。观察到索拉非尼组无进展生存期有改善趋势。索拉非尼组的毒性是可控的。
对这 15 例患者的分析显示，疗效和毒性结果与国际总体人群观察到的趋势一致。
